Dergiler / Anatolian Current Medical Journal / 2026 / Volume: 8 Issue: 5

Serum A disintegrin and metalloproteinase with thrombospondin motifs-7 and 12 levels are reduced in chronic hepatitis B but do not distinguish fibrosis severity

Fatih Kıvrakoğlu(Adana City Training and Research Hospital)0000-0002-5388-794X
Mustafa Ergin(Aksaray Training and Research Hospital)0000-0002-9593-3705
Serdar Kayıhan(Kırıkkale High Specialization State Hospital)0000-0001-6296-2588
Hanife Uzar(Republic of Türkiye Ministry of Health Gaziantep Provincial Health Administration)0000-0003-4358-5777
Zahide Şimşek(Bayındır Söğütözü Hospital)0000-0003-0212-064X
İlhami Yüksel(ANKARA YILDIRIM BEYAZIT UNIVERSITY, SCHOOL OF MEDICINE)0000-0002-9730-2309
Sayfa
—
Yayın Tarihi
2026-09-11
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

These reductions may reflect a generalized response to chronic viral infection rather than the specific extent of fibrotic tissue.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aims: This investigation sought to evaluate the potential associations between circulating A disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)-7, and ADAMTS-12 protein concentrations and the degree of structural hepatic fibrosis observed in patients with chronic hepatitis B (CHB).
📊
Temel Bulgular & Veri:Methods: This retrospective descriptive study included a cohort of 77 patients diagnosed with CHB, alongside 30 age-matched healthy participants.
💡
Sonuç & Katkı:These reductions may reflect a generalized response to chronic viral infection rather than the specific extent of fibrotic tissue.
🔬Tür:Research Article
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Chronic hepatitis B · hepatic fibrosis · non-invasive biomarkers

Abstract

Aims: This investigation sought to evaluate the potential associations between circulating A disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS)-7, and ADAMTS-12 protein concentrations and the degree of structural hepatic fibrosis observed in patients with chronic hepatitis B (CHB). Methods: This retrospective descriptive study included a cohort of 77 patients diagnosed with CHB, alongside 30 age-matched healthy participants. We utilized a sandwich enzyme-linked immunosorbent assay methodology to quantify the serum concentrations of both ADAMTS-7 and ADAMTS-12 in all study subjects. Fibrosis stage was assessed through liver biopsy, graded by the Ishak scoring system. Statistical analyses were conducted to compare groups and to evaluate the correlation between biomarker levels and fibrosis stage. Results: Compared with the healthy control group, patients with CHB exhibited significantly reduced serum concentrations of ADAMTS-7 and ADAMTS-12. However, no significant differences emerged between mild and advanced fibrosis. Conclusion: Serum ADAMTS-7 and ADAMTS-12 levels are significantly reduced in patients with CHB compared to healthy controls. However, since they do not differentiate between mild and advanced fibrosis, they have limited clinical utility as non invasive biomarkers for staging fibrosis severity. These reductions may reflect a generalized response to chronic viral infection rather than the specific extent of fibrotic tissue.

🔖

Bu Makaleye Atıf Yap

Kıvrakoğlu, F., Ergin, M., Kayıhan, S., Uzar, H., Şimşek, Z., Yüksel, İ. (2026). Serum A disintegrin and metalloproteinase with thrombospondin motifs-7 and 12 levels are reduced in chronic hepatitis B but do not distinguish fibrosis severity. Anatolian Current Medical Journal, Volume: 8 Issue: 5. https://doi.org/10.38053/acmj.1989511

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (19)

  1. Niederau C. Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit. World J Gastroenterol. 2014;20(33):11595-11617. doi:10.3748/wjg.v20.i33.11595
  2. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018;67(4):1560-1599. doi:10.1002/hep.29800
  3. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2025;83(2):502-583. doi:10.1016/j.jhep.2025.03.018
  4. Tapper EB, Lok AS. Use of liver imaging and biopsy in clinical practice. N Engl J Med. 2017;377(8):756-768. doi:10.1056/NEJMra1610570
  5. European Association for the Study of the Liver. EASL clinical practice guidelines on non-invasive tests for evaluation of liver disease severity and prognosis-2021 update. J Hepatol. 2021;75(3):659-689. doi:10.1016/j.jhep.2021.05.025
  6. Akhan S, Aynıoğlu A, Çağatay A, et al. Kronik hepatit B virusu infeksiyonunun yönetimi: Türk Klinik Mikrobiyoloji ve İnfeksiyon Hastalıkları Derneği Viral Hepatit Çalışma Grubu uzlaşı raporu. Klimik Derg. 2014;27(Suppl 1):2-18. doi:10.5152/kd.2014.26
  7. Yu H, Zhu Y. Expression of ADAMTS-7 and ADAMTS-12 in the nucleus pulposus during degeneration of rat caudal intervetebral disc. J Vet Med Sci. 2012;74(1):9-15. doi:10.1292/jvms.10-0556
  8. Gao YX, Yu CA, Lu JH, et al. ADAMTS-7 expression increases in the early stage of angiotensin II-induced renal injury in elderly mice. Kidney Blood Press Res. 2013;38(1):121-131. doi:10.1159/000355758
  9. Gökdemir İE, Özdeğirmenci Ö, Elmas B, et al. Evaluation of ADAMTS12, ADAMTS16, ADAMTS18 and IL-33 serum levels in pre-eclampsia. J Matern Fetal Neonatal Med. 2016;29(15):2451-2456. doi:10.3109/14767058.2015.1087497
  10. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995;22(6):696-699. doi:10.1016/0168-8278(95)80226-6
  11. Sterling RK, King WC, Wahed AS, et al. Evaluating noninvasive markers to identify advanced fibrosis by liver biopsy in HBV/HIV co-infected adults. Hepatology. 2020;71(2):411-421. doi:10.1002/hep.30825
  12. Kisseleva T, Brenner D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat Rev Gastroenterol Hepatol. 2021;18(3):151-166. doi:10.1038/s41575-020-00372-7
  13. Kelwick R, Desanlis I, Wheeler GN, Edwards DR. The ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) family. Genome Biol. 2015;16(1):113. doi:10.1186/s13059-015-0676-3
  14. Parola M, Pinzani M. Liver fibrosis: pathophysiology, pathogenetic targets and clinical issues. Mol Aspects Med. 2019;65:37-55. doi:10.1016/j.mam.2018.09.002
  15. Wong GL, Lemoine M. The 2024 updated WHO guidelines for the prevention and management of chronic hepatitis B: main changes and potential implications for the next major liver society clinical practice guidelines. J Hepatol. 2025;82(5):918-925. doi:10.1016/j.jhep.2024.12.004
  16. Xiao G, Yang J, Yan L. Comparison of diagnostic accuracy of aspartate aminotransferase to Platelet Ratio Index and Fibrosis-4 Index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta-analysis. Hepatology. 2015;61(1):292-302. doi:10.1002/hep.27382
  17. Yuen MF, Chen DS, Dusheiko GM, et al. Hepatitis B virus infection. Nat Rev Dis Primers. 2018;4:18035. doi:10.1038/nrdp.2018.35
  18. Hayashi H, Beppu T, Shirabe K, Maehara Y, Baba H. Management of thrombocytopenia due to liver cirrhosis: a review. World J Gastroenterol. 2014;20(10):2595-2605. doi:10.3748/wjg.v20.i10.2595
  19. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ; Risk Evaluation of Viral Load Elevation and Associated Liver Disease/Cancer-In HBV (the REVEAL-HBV) Study Group. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006; 130(3):678-686. doi:10.1053/j.gastro.2005.11.016